newsfilter
← Latest News
GlobeNewswire·

Imara Reports Third Quarter 2021 Financial Results and Business Highlights

Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021 Introduction of pipeline program IMR-261, a novel oral clinic-ready Nrf2 act